The new therapeutic agents should ideally be capable of treating BCR-ABL-independent mechanisms of resistance, such as Pgp overexpression, besides showing significant activity in CML cells. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.